Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Sports Medicine
Published in: Sports Medicine 5/2009

01-05-2009 | Leading Article

Platelet-Rich Therapies in the Treatment of Orthopaedic Sport Injuries

Authors: Mikel Sánchez, Eduardo Anitua, Gorka Orive, Iñigo Mujika, Dr Isabel Andia

Published in: Sports Medicine | Issue 5/2009

Login to get access

Abstract

Biomedical sciences have made major advances in understanding how tissues repair, and the signalling mechanisms required to achieve this goal are progressively being dissected. Advances in the understanding of tissue repair mechanisms and the pivotal role of growth factors have stimulated the use of platelet-rich therapies by orthopaedic surgeons and sports physicians, mainly with the aim of stimulating and enhancing tissue healing. Autologous activated platelets retained in fibrin matrices are used as a source of molecular signals that control cell fate, including cell growth, cell differentiation and the synthesis of diverse functional proteins. Thus far, platelet-rich technologies have spawned additional ambitious endeavours, including surgical and nonsurgical treatments in sports orthopaedics. Reconstruction of anterior cruciate ligament and tendon surgery and treatment of joint injuries, tendinopathy or muscle tears are but a few examples of the potential applications of this technology in the field of orthopaedic sports medicine. In the present article, some of the most important therapeutic applications using these approaches–especially preparation rich in growth factor (PRGF) technology–are presented, as are some of the limitations, anti-doping concerns and future challenges in the field. In view of a general state of confusion, the concept of platelet-rich plasma needs rigorous definition associated with well characterized products and re-administration procedures. There is evidence that reconstruction of anterior cruciate ligament and tendon surgery combined with PRGF enhances healing and functional recovery; clinical evidence is also appearing in the literature regarding treatment of tendinopathies and osteoarthritis. Currently, the challenge lies in conducting randomized, controlled clinical trials to determine the essential qualities of these technologies. If anti-doping agencies clarify their regulatory guidelines, robust studies in athletes are expected to emerge. Although much research work lies ahead, the current knowledge points to a future in which platelet-rich therapies will continue improving existing conventional approaches to treatment of sports injuries.
Literature
1.
Cassel EP, Finch CF, Stathakis VZ. Epidemiology of medically treated sport and active recreation injuries in the Latrobe Valley, Victoria, Australia. Br J Sports Med 2003; 37: 405–9CrossRef
2.
Fanelli GC, Orcutt DR, Harris JD. The athletically active middle aged arthritic knee: introduction, demographics, sports participation epidemiology and types of injuriesseen. Sports Med Arthroscop Rev 2003; 11 (2): 98–101CrossRef
3.
Timpka T, Ekstrand J, Svanström L. From sports injury prevention to safety promotion in sports. Sports Med 2006; 36 (9): 733–45PubMedCrossRef
4.
Fredericson M, Misra AK. Epidemiology and aetiology of marathon running injuries. Sports Med 2007; 37: 437–9PubMedCrossRef
5.
Goldber AS, Moroz L, Smith A, et al. Injury surveillance in young athletes. Sports Med 2007; 37: 265–78CrossRef
6.
Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003; 83: 835–70PubMed
7.
8.
Tabata Y. Tissue regeneration based on growth factor release. Tissue Eng 2003; 9: S5–15CrossRef
9.
Anitua E, Sanchez M, Nurden AT, et al. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 2006; 24: 227–34PubMedCrossRef
10.
Anitua E, Sánchez M, Orive G, et al. Therapeutic applications of the preparation rich in growth factors (PRGF). In:Jie Hu, editor. Recent advances in biomaterial research. Kerala: Transworld Research Network, 2008: 141–53
11.
Kajikawa Y, Morihara T, Sakamoto H, et al. Platelet-rich plasma enhances the initial mobilization of circulation-derived cells for tendon healing. J Cell Physiol 2008; 59: 1329–39
12.
Hoffman A, Gross G. Tendon and ligament engineering in the adult organism: mesenchymal stem cells and gene-therapeutic approaches. Int Orthop 2007; 31: 791–7CrossRef
13.
Rehfeldt F, Engler AJ, Eckardt A, et al. Cell responses to the mechanochemical microenvironment: implications for regenerative medicine and drug delivery. Adv Drug Deliv Rev 2007; 59: 1329–39PubMedCrossRef
14.
Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet derived growth factor. Physiol Rev 1999; 79 (4): 1283–316PubMed
15.
Shi Y, Massague J. Mechanisms of TGF-beta signalling from cell membrane to the nucleus. Cell 2003; 113 (6): 685–700PubMedCrossRef
16.
Danielpour D, Song K. Cross-talk between IGF-I and TGF-beta signaling pathways. Cytokine Growth Factor Rev 2006; 17: 59–74PubMedCrossRef
17.
Gerritsen ME, Tomlinson JE, Zlot C, et al. Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. Br J Pharmacol 2003; 140: 595-10PubMedCrossRef
18.
Gianchandani EP, Brautigan DL, Papin JA. Systems analyses characterize integrated functions of biochemical networks. Trends Biochem Sci 2006; 31: 284–91PubMedCrossRef
19.
Aspenberg P. Stimulation of tendon repair: mechanical loading, GDFs and platelets. A mini-review. Acta Orthop 2007; 31 (6): 783–9
20.
21.
Whitman DH, Berry RL, Green DM. Platelet gel: an autologous alternative to fibrin glue with applications in oral and maxillofacial surgery. J Oral Maxillofac Surg 1997; 55 (11): 1294–99PubMedCrossRef
22.
Anitua E. Plasma rich in growth factors: preliminary results of the use in the preparation of future sites for implants. Int J Oral Maxillofac Implants 1999; 14: 529–35PubMed
23.
Marx RE, Carlson ER, Eichstaedt RN, et al. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endodon 1998; 85: 638–46CrossRef
24.
El-Sharkawy H, Kantarci A, Deady J, et al. Platelet rich plasma: growth factors and pro- and anti-inflammatory properties. J Periodontol 2007; 78: 661–9PubMedCrossRef
25.
Bielecki TM, Gazdzik TS, Arendt J, et al. Antibacterial effect of autologous platelet gel enriched with growth factors and other active substances. J Bone Joint Surg 2007; 89: 417–20CrossRef
26.
Anitua E, Andía I, Ardanza B, et al. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 2004; 91: 4–15PubMed
27.
Nurden AT, Nurden P, Sanchez M, et al. Platelet and wound healing. Front Biosci 2008; 13: 3532–48PubMed
28.
Laurens N, Koolwijk P, De Maat MPM. Fibrin structure and wound healing. J Thromb Haemost 2006; 4: 932–9PubMedCrossRef
29.
Asfaha S, Cena N, Houl S, et al. Protease-activated receptor-4: a novel mechanism of inflammatory pain modulation. Br J Pharmacol 2006; 150: 176–85PubMedCrossRef
30.
Trowbridge CC, Stammers AH, Woods E, et al. Use of platelet gel and its effects on infection in cardiac surgery. J Extra Corpor Technol 2005; 37 (4): 381–6PubMed
31.
Tang YQ, Yeaman MR, Selsted ME. Antimicrobial peptides from human platelets. Infect Immun 2002; 70: 6515–7CrossRef
32.
Everts AM, Zundert AV, Schönberger JPAM, et al. What do we use: platelet-rich plasma or platelet leukocyte gel? J Biomed Mat Res A 2008; 85: 1135–6CrossRef
33.
Bramono DS, Richmond JC, Weitzel PI, et al. Matrix metalloproteinases and their clinical applications in orthopaedics. Clin Orthop Relat Res 2004; 428: 272–85PubMedCrossRef
34.
Tidball JG. Inflammatory cell response to acute muscle injury. Med Sci Sports Exerc 1995; 27: 1022–32PubMedCrossRef
35.
Tidball JG. Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol 2005; 288: R345–53CrossRef
36.
Pizza FX, McLoughlin TJ, McGregor SJ, et al. Neutrophils injured cultured skeletal myotubes. Am J Physiol Cell Physiol 2001; 281: C353–41
37.
Schneider BP, Tiidus PM. Neutrophil infiltration in exercise injured skeletal muscle. Sports Med 2007; 37 (10): 837–56PubMedCrossRef
38.
Veillet CJ, McKee MD. Growth factors-BMPs, DBMs, and buffy coat products: are there any proven differences amongst them? Injury Int J Care Injured 2007; 38 Suppl. 1: S38–48
39.
Anitua E, Sánchez M, Orive G, et al. Shedding light in the controversial terminology for platelet rich products. J Biomed Mat Res A. In press
40.
Anitua E, Sanchez M, Orive G, et al. Delivering growth factors for therapeutics. Trends Pharmacol Sci 2008; 29 (1): 37–41PubMedCrossRef
41.
Anitua E, Aguirre JJ, Algorta J, et al. Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers. J Biomed Mater Res B: Appl Biomater 2008; 84B: 415–21CrossRef
42.
Anitua E, Sanchez M, Orive G, et al. The potential impact of the preparations rich in growth factors (PRGF) in different medical fields. Biomaterials 2007; 28: 4551–60PubMedCrossRef
43.
Creaney L, Hamilton B. Growth factor delivery methods in the management of sports injuries: the state of the play. Br J Sports Med 2008; 42: 314–20PubMedCrossRef
44.
Molloy T, Wang Y, Murrell GAC. The roles of growth factors in tendon and ligament healing. Sports Med 2003; 33: 381–94PubMedCrossRef
45.
Anitua E, Andia I, Sanchez M, et al. Autologous preparations rich in growth factors promote proliferation and induce VEGF and HGF production by human tendon cells in culture. J Orthop Res 2005; 23: 281–6PubMedCrossRef
46.
Conway K, Price P, Harding KG, et al. The molecular and clinical impact of hepatocyte growth factor, its receptors, activators, and inhibitors in wound healing. Wound Rep Reg 2006; 14: 2–10CrossRef
47.
Anitua E, Sanchez M, Nurden AT, et al. Autologous fibrin matrices: a potential source of biological mediators that modulate tendon cell activities. J Biomed Mat Res A 2006; 77: 285–93CrossRef
48.
Anitua E, Sanchez M, Nurden AT, et al. Reciprocal actions of platelet-secreted TGF-beta1 on the production ofVEGF and HGF by human tendon cells. Plast Reconstr Surg 2007; 119: 950–9PubMedCrossRef
49.
Virchenko O, Aspenberg P. How can one platelet injection after tendon injury lead to a stronger tendon after 4 weeks? Interplay between early regeneration and mechanical stimulation. Acta Orthop 2006; 77 (5): 806–12
50.
Sanchez M, Anitua E, Azofra J, et al. Comparison of surgically repaired Achilles tendon tears using PRGF. Am J Sports Med 2007; 35 (2): 245–51PubMedCrossRef
51.
52.
53.
Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med 2006; 34 (11): 1774–8PubMedCrossRef
54.
Suresh SPS, Ali KE, Jones H, et al. Medial epicondylitis: is ultrasound guided autologous blood injection an effective treatment? Br J Sports Med 2006; 40: 935–9PubMedCrossRef
55.
Griffin LY. Noncontact anterior cruciate ligament injuries: risk factors and prevention strategies. J Am Acad Orthop Surg 2008; 8: 141–50
56.
Johnson DL, Urban Jr WP, et al. Articular cartilage changes seen with magnetic resonance imaging detected bone bruises associated with acute anterior cruciate ligament rupture. Am J Sports Med 1998; 26 (3): 409–14PubMed
57.
Brown CH, Carson EW. Revision anterior cruciate ligament surgery. Clin Sports Med 1999; 18: 109–17PubMedCrossRef
58.
59.
Vunjak-Novakovic G, Altman G, Horan R, et al. Tissue engineering of ligaments. Ann Rev Biomed Eng 2004; 6: 131–56CrossRef
60.
Murray MM, Spindler KP, Devin C, et al. Use of a collagen platelet rich plasma scaffold to stimulate healing of a central defect in the canine ACL. J Orthop Res 2006; 24 (4): 820–30PubMedCrossRef
61.
Sánchez M, Azofra J, Aizpurua B, et al. Use of autologous plasma rich in growth factors in arthroscopic surgery. Cuadernos Artroscop 2003; 10: 12–9
62.
Sánchez M, Azofra J, Anitua E, et al. Plasma rich in growth factors to treat an articular cartilage avulsion: a case report. Med Sci Sports Exerc 2003; 35: 1648–52PubMedCrossRef
63.
Cugat R, Carrillo JM, Serra I, et al. Articular cartilage defects reconstruction by plasma rich in growth factors. In: Zanasi S, Brittberg M, Marcacci M, editors. Basic science, clinical repair and reconstruction of articular cartilage defects: current status and prospects. Bologna: Timeo Editore, 2006: 801–7
64.
Akeda K, An HS, Okuma M, et al. Platelet-rich plasma stimulates porcine articular chondrocyte proliferation and matrix biosynthesis. Osteoarthritis Cartilage 2007; 14: 1272–80CrossRef
65.
Ishida K, Kuroda R, Miwa M, et al. The regenerative effects of platelet-rich plasma on meniscal cells in vitro and itsin vivo application with biodegradable gelatin hydrogel. Tissue Eng 2007; 13 (5): 1103–12PubMedCrossRef
66.
Rall K, McElroy G, Keats TE. A study of the long-term effects of football injury in the knee. Mol Med 1984; 61: 435–38
67.
Shephard GJ, Banks AJ, Ryan WG. Ex-professional association footballers have an increased prevalence of osteoarthritis of the hip compared with age-matched controls despite not having sustained notable hip injuries. Br J Sports Med 2003; 37: 80–1CrossRef
68.
Anitua E, Sanchez M, Nurden AT, et al. Platelet-released growth factors enhance the secretion of hyaluronic acid and induce hepatocyte growth factor production by synovial fibroblasts from arthritic patients. Rheumatology 2007; 46: 1769–72PubMedCrossRef
69.
Anitua E, Sanchez M, Azofra J, et al. Autologous preparation rich in growth factors for treating knee osteoarthritis: clinical-biological study [abstract]. World congress on osteoarthritis: osteoarthritis cartilage; 2007 Dec; Fort Lauderdale (FL), 15 Suppl. C: 6–9 C218
70.
Sanchez M, Anitua E, Azofra J, et al. Clinical benefits of using an autologous preparation rich in growth factors to treat knee osteoarthritis [abstract]. World congresson osteoarthritis: osteoarthritis cartilage; 2007 Dec; Fort Lauderdale (FL), 15 Suppl. C: 6–9 C148
71.
Sánchez M, Anitua E, Azofra J, et al. Intra-articular injection of an autologous preparation rich in growth factors for the treatment of knee OA: a retrospective cohort study. Clin Exp Rheumatol 2008; 26: 910–3PubMed
72.
73.
74.
Denley A, Cosgrove LJ, Booker GW, et al. Molecular interactions of the IGF system. Cytokine Growth Factor Rev 2005; 16: 421–39PubMedCrossRef
75.
Olesen JL, Heinemeier KM, Langberg H, et al. Expression, content and localization of insulin-like growth factor I in human Achilles tendon. Connect Tissue Rep 2006; 47: 200–6CrossRef
76.
Wildemann B, Kadow-Romacker A, Pruss A, et al. Quantification of growth factors in allogenic bone grafts extracted with three different methods. Cell Tissue Bank 2007; 8 (2): 104–14CrossRef
Metadata
Title
Platelet-Rich Therapies in the Treatment of Orthopaedic Sport Injuries
Authors
Mikel Sánchez
Eduardo Anitua
Gorka Orive
Iñigo Mujika
Dr Isabel Andia
Publication date
01-05-2009
Publisher
Springer International Publishing
Published in
Sports Medicine / Issue 5/2009
Print ISSN: 0112-1642
Electronic ISSN: 1179-2035
DOI
https://doi.org/10.2165/00007256-200939050-00002

Other articles of this Issue 5/2009

Sports Medicine 5/2009 Go to the issue

Review Article

Swimming Exercise

Review Article

Exercise and Fatigue

Current Opinion

Genetic Testing and Sports Medicine Ethics

Review Article

Characteristics of Physical Activity Guidelines and their Effect on Adherence